ClinConnect ClinConnect Logo
Search / Trial NCT05503095

PCSK9 Polymorphism and Risk of Cardiac Rupture

Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Aug 15, 2022

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

Pcsk9 Cardiac Rupture

ClinConnect Summary

This clinical trial is studying a specific gene called PCSK9 and its possible connection to a serious condition known as post-infarction heart rupture, which can happen after a heart attack. Researchers want to understand why some patients experience this dangerous complication while others do not, especially since it can occur shortly after a heart attack. They think that variations in the PCSK9 gene might play a role in how the heart reacts to damage from a heart attack.

To participate in this study, you should be between the ages of 65 and 74 and have been diagnosed with either a heart attack with a certain type of heart damage (known as ST elevation) or a heart attack that has led to cardiac rupture. If you join the trial, you will help researchers learn more about the heart's healing process and how genetic differences might influence recovery after a heart attack. This could lead to better treatment options in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • clinical diagnosis of acute myocardial infarction with ST sopra-elevation (control group)
  • clinical diagnosis of acute myocardial infarction complicated by cardiac rupture
  • Exclusion Criteria:
  • absence of coronary artery disease

About Maastricht University Medical Center

Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.

Locations

Varese, , Italy

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials